QualityStocksNewsBreaks – VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study
VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, achieving 97% specificity and identifying 86% of cases, advancing development of a blood-based liquid biopsy test for feline cancer. The company said the technology addresses a significant unmet need in veterinary medicine and represents a commercial opportunity, with potential milestone payments and future revenue generation, as it works toward product commercialization and expands its presence in the growing companion animal oncology market. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5…